Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Lung cancer symbols : AZN save search
Non-small Cell Lung Cancer Drugs Market to Grow by USD 30.23 billion| Increasing Prevalence and Incidence of Non-small Cell Lung Cancer to Boost Market Growth | Technavio
Published: 2022-03-08 (Crawled : 08:00) - prnewswire.com
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -2.09%
H: 5.03%
C: 0.85%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.01%
H: 0.81%
C: -0.06%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.29%
H: 0.6%
C: -1.24%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
drug cel lung cancer cancer drug cancer growth
HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer
Published: 2022-03-07 (Crawled : 05:00) - globenewswire.com
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: -1.8%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -10.68%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.33%
H: 0.0%
C: 0.0%
orpathys star lung cancer one cancer milestone
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2022-03-02 (Crawled : 14:00) - biospace.com/
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.37%
H: 2.02%
C: 2.02%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 3.95%
H: 5.06%
C: -7.17%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
tagrisso gene therapy trial cel lung cancer phase 1 therapy cancer
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.49%
H: 1.06%
C: -2.49%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 16.79%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: 0.07%
keytruda fast track designation treatment fda fast track gene therapy cel fda fast track lung cancer therapy cancer designation
DESTINY-Lung04 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2021-12-23 (Crawled : 14:00) - biospace.com/
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.0%
H: 0.71%
C: 0.24%
enhertu trial cel lung cancer cancer phase 3 initiated her2- her2
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
Published: 2021-11-24 (Crawled : 01:00) - globenewswire.com
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.02%
H: 1.33%
C: 1.33%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -4.39%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
orpathys lung cancer china therapy cancer trial
Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2021-10-25 (Crawled : 13:00) - biospace.com/
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.11%
H: 0.03%
C: -0.27%
lung cancer collaboration cancer trial initiated keytruda
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
Published: 2021-09-08 (Crawled : 11:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -2.29%
H: 1.34%
C: 1.29%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.85%
H: 0.17%
C: -0.42%
lung cancer china therapy cancer trial
HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations
Published: 2021-06-22 (Crawled : 18:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 3.66%
H: 1.31%
C: -4.82%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.26%
H: 0.28%
C: -0.46%
lung cancer china cancer
Press news Biocartis Group NV: Biocartis Announces New Collaboration with AstraZeneca to Expand Availability of Idylla™ EGFR Biomarker Testing Among Patients with Lung Cancer
Published: 2021-05-04 (Crawled : 06:00) - globenewswire.com
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.8%
H: 0.21%
C: -0.64%
lung cancer test collaboration cancer biomarkers
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.